Budget impact analysis of osteoporosis medications for primary prevention of fractures in Taiwan

Kun Ling Wu, Chih Hsing Wu, Yin Fan Chang, Yun Ting Lin, Jason C. Hsu

Research output: Contribution to journalArticle

Abstract

Introduction: Taiwan's national health insurance currently only covers the use of osteoporosis drugs for the secondary prevention of fractures and does not provide coverage for primary prevention. The purpose of this study is to develop a model for analyzing the budgetary impact of the use of osteoporosis medications of primary prevention. Methods: The budget impact model in this study is the “actual medication cost” minus the “medical expenses for all types of fractures that can be avoided by taking osteoporosis medications.” We developed six possible insurance payment plans for primary prevention based on the age of the patients and T-scores and performed eleven steps to estimate the budget impact of each payment plan. Results: The results of this study indicated that there may be 71,220 (T-score ≤ − 3.0, 75 + y/o) to 157,515 (T-score ≤ − 2.5, 65 + y/o) people using the drugs, and the budget impact may be US$26.28–58.98 million in 2019. However, the payment plans may avoid 492–766 fracture events and save medical expenditures for fracture treatment by US$1.30–2.02 million. The average costs for primary prevention within a year will be US$53,386–77,006. Conclusion: The budget impact of using osteoporosis medications to primary prevention of fractures is significant, but it can be compensated due to savings in fracture treatment costs.

Original languageEnglish
JournalJournal of Bone and Mineral Metabolism
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Budgets
Primary Prevention
Taiwan
Osteoporosis
Costs and Cost Analysis
National Health Programs
Health Expenditures
Secondary Prevention
Insurance
Pharmaceutical Preparations
Health Care Costs

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

@article{5ab972533cbb491593ef847563d8212b,
title = "Budget impact analysis of osteoporosis medications for primary prevention of fractures in Taiwan",
abstract = "Introduction: Taiwan's national health insurance currently only covers the use of osteoporosis drugs for the secondary prevention of fractures and does not provide coverage for primary prevention. The purpose of this study is to develop a model for analyzing the budgetary impact of the use of osteoporosis medications of primary prevention. Methods: The budget impact model in this study is the “actual medication cost” minus the “medical expenses for all types of fractures that can be avoided by taking osteoporosis medications.” We developed six possible insurance payment plans for primary prevention based on the age of the patients and T-scores and performed eleven steps to estimate the budget impact of each payment plan. Results: The results of this study indicated that there may be 71,220 (T-score ≤ − 3.0, 75 + y/o) to 157,515 (T-score ≤ − 2.5, 65 + y/o) people using the drugs, and the budget impact may be US$26.28–58.98 million in 2019. However, the payment plans may avoid 492–766 fracture events and save medical expenditures for fracture treatment by US$1.30–2.02 million. The average costs for primary prevention within a year will be US$53,386–77,006. Conclusion: The budget impact of using osteoporosis medications to primary prevention of fractures is significant, but it can be compensated due to savings in fracture treatment costs.",
author = "Wu, {Kun Ling} and Wu, {Chih Hsing} and Chang, {Yin Fan} and Lin, {Yun Ting} and Hsu, {Jason C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00774-019-01061-5",
language = "English",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Budget impact analysis of osteoporosis medications for primary prevention of fractures in Taiwan

AU - Wu, Kun Ling

AU - Wu, Chih Hsing

AU - Chang, Yin Fan

AU - Lin, Yun Ting

AU - Hsu, Jason C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Taiwan's national health insurance currently only covers the use of osteoporosis drugs for the secondary prevention of fractures and does not provide coverage for primary prevention. The purpose of this study is to develop a model for analyzing the budgetary impact of the use of osteoporosis medications of primary prevention. Methods: The budget impact model in this study is the “actual medication cost” minus the “medical expenses for all types of fractures that can be avoided by taking osteoporosis medications.” We developed six possible insurance payment plans for primary prevention based on the age of the patients and T-scores and performed eleven steps to estimate the budget impact of each payment plan. Results: The results of this study indicated that there may be 71,220 (T-score ≤ − 3.0, 75 + y/o) to 157,515 (T-score ≤ − 2.5, 65 + y/o) people using the drugs, and the budget impact may be US$26.28–58.98 million in 2019. However, the payment plans may avoid 492–766 fracture events and save medical expenditures for fracture treatment by US$1.30–2.02 million. The average costs for primary prevention within a year will be US$53,386–77,006. Conclusion: The budget impact of using osteoporosis medications to primary prevention of fractures is significant, but it can be compensated due to savings in fracture treatment costs.

AB - Introduction: Taiwan's national health insurance currently only covers the use of osteoporosis drugs for the secondary prevention of fractures and does not provide coverage for primary prevention. The purpose of this study is to develop a model for analyzing the budgetary impact of the use of osteoporosis medications of primary prevention. Methods: The budget impact model in this study is the “actual medication cost” minus the “medical expenses for all types of fractures that can be avoided by taking osteoporosis medications.” We developed six possible insurance payment plans for primary prevention based on the age of the patients and T-scores and performed eleven steps to estimate the budget impact of each payment plan. Results: The results of this study indicated that there may be 71,220 (T-score ≤ − 3.0, 75 + y/o) to 157,515 (T-score ≤ − 2.5, 65 + y/o) people using the drugs, and the budget impact may be US$26.28–58.98 million in 2019. However, the payment plans may avoid 492–766 fracture events and save medical expenditures for fracture treatment by US$1.30–2.02 million. The average costs for primary prevention within a year will be US$53,386–77,006. Conclusion: The budget impact of using osteoporosis medications to primary prevention of fractures is significant, but it can be compensated due to savings in fracture treatment costs.

UR - http://www.scopus.com/inward/record.url?scp=85074823926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074823926&partnerID=8YFLogxK

U2 - 10.1007/s00774-019-01061-5

DO - 10.1007/s00774-019-01061-5

M3 - Article

C2 - 31709455

AN - SCOPUS:85074823926

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

ER -